RSV G Specific Neutra™ Antibody Products

Are prolonged therapeutic development timelines or challenges in targeting the respiratory syncytial virus G protein hindering your progress? Creative Biolabs' RSV G-specific Neutra™ antibody products utilize innovative protein engineering and validated high-affinity epitope targeting to accelerate antiviral drug development, enabling rapid identification of potent neutralizers for RSV inhibition.

Introduction to RSV G

The respiratory syncytial virus G protein (RSV G) is a critical surface glycoprotein mediating viral attachment and host cell entry. As a pivotal virulence factor, it facilitates RSV's interaction with CX3CR1 chemokine receptors and glycosaminoglycans on respiratory epithelial cells.

Fig.1 RSV G protein motifs and attachment mechanisms.¹

• Structural Insights

Structurally, RSV G comprises a conserved central domain flanked by variable mucin-like regions, adopting a type III transmembrane topology. Cryo-EM studies reveal its dynamic conformational flexibility, enabling immune evasion through glycan shielding and epitope masking.

• Related Signaling Pathways

RSV G activates host pro-inflammatory pathways by mimicking CX3C chemokine motifs, triggering NF-κB and MAPK cascades that exacerbate bronchiolitis in infected tissues. This protein also modulates immune evasion by suppressing interferon responses, prolonging viral persistence.

• Associated Pathologies

RSV is the leading cause of severe lower respiratory tract infections in infants, immunocompromised individuals, and older adults, contributing to annual hospitalization rates exceeding 3 million globally. Its G protein drives pathogenesis by promoting syncytium formation and viral spread, making it a high-priority therapeutic target.

Applications of RSV G-Neutralizing Antibodies

• Therapeutic Intervention in Active Infections

Neutralizing antibodies reduce viral load by competitively inhibiting RSV G-host receptor interactions. Clinical studies demonstrate that early administration lowers hospitalization risks in high-risk pediatric populations by 60%, underscoring their potential as first-line biologics for acute RSV management.

• Prophylactic Protection for High-Risk Groups

Pre-exposure prophylaxis with anti-RSV G antibodies provides immediate immunity in preterm infants and elderly patients. Engineered half-life extension ensures long-lasting protection during peak RSV seasons, overcoming the limits of short-acting small-molecule antivirals.

• Diagnostic Assay Development

High-specificity anti-G antibodies enable rapid antigen detection in nasopharyngeal swabs, achieving >95% sensitivity in point-of-care tests. These tools are critical for early outbreak identification and real-time surveillance in clinical settings.

• Vaccine Efficacy Profiling

Quantifying G-specific neutralizing titers in vaccine trial cohorts correlates with long-term immune protection. Creative Biolabs' antibodies serve as reference standards for validating next-generation RSV vaccines, ensuring robust immunogenicity assessment.

Our Anti-RSV G Antibodies

Creative Biolabs offers RSV G-specific Neutra™ antibody products with unmatched specificity and effectiveness, empowering researchers to overcome critical bottlenecks in antiviral development. With customizable formats for ELISA, neutralization assays, and in vivo studies, these tools are indispensable for accelerating therapeutic and diagnostic innovations.

Antibodies targeting RSV G's central conserved domain neutralize infection by blocking receptor engagement. Unlike prefusion F-protein-targeting antibodies, anti-G antibodies exhibit cross-strain efficacy against both RSV-A and RSV-B subtypes. Creative Biolabs' antibodies demonstrate sub-nanomolar affinity, validated in inhibiting RSV G-mediated entry across primary airway epithelial models. Their engineered Fc domains enhance mucosal bioavailability, enabling prophylactic and therapeutic applications.

Contact our team today to discuss tailored solutions for your RSV research.

REFERENCE

1. King, Tiffany, et al. "The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines." PLoS pathogens 17.4 (2021): e1009469. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1371/journal.ppat.1009469